Ocuphire’s APX3330 for Retinal Diseases to be Presented at ARVO 2021

Source: Ocuphire

Ocuphire Pharma announced that data from preclinical studies and pharmacokinetic modeling of the company’s proprietary APX3330 drug candidate will be presented on Sunday, May 2, 2021 during the Association for Research in Vision and Ophthalmology (ARVO) virtual Annual Meeting, May 1-7, 2021.

Details of the abstract and presentation are as follows:

Title: Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling
Session: Diabetic Retinopathy
Presentation Type: Paper Presentation
Date: 11:15 AM – 12:45 PM EDT on Sunday, May 2

On Saturday, May 1, 2021 at 7 am ET, the virtual presentations will be available on demand to registered attendees of the ARVO Annual Meeting. Ocuphire plans to post the APX3330 abstract presentation to Ocuphire’s website under Posters and Publications.

Data from this preclinical study showed that oral administration of APX3330 was effective in reducing laser-induced choroidal neovascularization (L-CNV) in a mouse model, which is a widely validated model for studying antiangiogenic therapies. Additionally, new data will be presented from PBPK modeling that confirmed the dosing strategy for the ongoing ZETA-1 phase 2 trial in patients with diabetic retinopathy (DR) and diabetic macular edema (DME).

“We are very pleased to share new data on the PBPK modeling results of APX3330, which quantitatively predict the amount of drug that would be reaching the retina,” Dr. Mark R. Kelley, Professor in the Department of Pediatrics and Glick Eye Institute at Indiana University School of Medicine, founder of the APX3330 program, and member of Ocuphire’s Medical Advisory Board, said in a company news release. “At present, DR patients are less frequently treated with anti-VEGF intravitreal injections, so we are excited to initially develop APX3330 as a potential oral treatment option for DR patients.”


Related Content